Tags

Type your tag names separated by a space and hit enter

[Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
Gan To Kagaku Ryoho. 2012 Mar; 39(3):405-8.GT

Abstract

This study compared the efficacy and safety of a 3-day-type transdermal fentanyl patch conversion by the rapid titration method to short-acting oral oxycodone for cancer pain.We evaluated seven hospitalized cancer patients who had moderate to severe cancer pain.Pain intensity was rated using an 11-point(0-10)numerical rating scale(NRS).All 7 patients initially reported their pain intensity at rest as NRS≥4 during treatment by Non-Steroidal Anti-Inflammatory Drugs(NSAIDs).Short - acting oral oxycodone(OxiNorm®)5 mg was administered to all patients.One hour after short-acting oral oxycodone was administered, pain assessment was carried out using NRS by the author.Short -acting oral oxycodone was administered four times a day periodically, and as a rescue dose.If the total daily dose of short-acting oral oxycodone was stable for 2 days, we switched to the 3-day-type transdermal fentanyl patch.The optimal dosage of the 3-day-type transdermal fentanyl patch was determined by titration of short-acting oral oxycodone.All 7 patients reported mild levels(NRS≤2)of cancer pain for 2 days.No serious side effects were reported.The 3-day-type transdermal fentanyl patch conversion by the rapid titration method with short-acting oral oxycodone can be accomplished safely and effectively for patients with moderate cancer pain.

Links

Publisher Full Text

Authors+Show Affiliations

Yamazaki K
Dept. of Surgery and Breast Surgery, Bellland General Hospital.
Fujio N
No affiliation info available
Ishikawa N
No affiliation info available
Watanabe H
No affiliation info available
Kameyama M
No affiliation info available

MeSH

Administration, CutaneousAdministration, OralAgedAged, 80 and overAnalgesics, OpioidDrug Therapy, CombinationFemaleFentanylHumansMaleMiddle AgedNeoplasmsOxycodonePainTime Factors

Pub Type(s)

Clinical Trial
English Abstract
Journal Article

Language

jpn

PubMed ID

22421768

Citation

Yamazaki, Keiichi, et al. "[Three-day-type Transdermal Fentanyl Patch Conversion By Rapid Titration Method With Short-acting Oral Oxycodone for Cancer Pain]." Gan to Kagaku Ryoho. Cancer & Chemotherapy, vol. 39, no. 3, 2012, pp. 405-8.
Yamazaki K, Fujio N, Ishikawa N, et al. [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain]. Gan To Kagaku Ryoho. 2012;39(3):405-8.
Yamazaki, K., Fujio, N., Ishikawa, N., Watanabe, H., & Kameyama, M. (2012). [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain]. Gan to Kagaku Ryoho. Cancer & Chemotherapy, 39(3), 405-8.
Yamazaki K, et al. [Three-day-type Transdermal Fentanyl Patch Conversion By Rapid Titration Method With Short-acting Oral Oxycodone for Cancer Pain]. Gan To Kagaku Ryoho. 2012;39(3):405-8. PubMed PMID: 22421768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain]. AU - Yamazaki,Keiichi, AU - Fujio,Nagahisa, AU - Ishikawa,Nana, AU - Watanabe,Hiroyuki, AU - Kameyama,Masao, PY - 2012/3/17/entrez PY - 2012/3/17/pubmed PY - 2012/5/25/medline SP - 405 EP - 8 JF - Gan to kagaku ryoho. Cancer & chemotherapy JO - Gan To Kagaku Ryoho VL - 39 IS - 3 N2 - This study compared the efficacy and safety of a 3-day-type transdermal fentanyl patch conversion by the rapid titration method to short-acting oral oxycodone for cancer pain.We evaluated seven hospitalized cancer patients who had moderate to severe cancer pain.Pain intensity was rated using an 11-point(0-10)numerical rating scale(NRS).All 7 patients initially reported their pain intensity at rest as NRS≥4 during treatment by Non-Steroidal Anti-Inflammatory Drugs(NSAIDs).Short - acting oral oxycodone(OxiNorm®)5 mg was administered to all patients.One hour after short-acting oral oxycodone was administered, pain assessment was carried out using NRS by the author.Short -acting oral oxycodone was administered four times a day periodically, and as a rescue dose.If the total daily dose of short-acting oral oxycodone was stable for 2 days, we switched to the 3-day-type transdermal fentanyl patch.The optimal dosage of the 3-day-type transdermal fentanyl patch was determined by titration of short-acting oral oxycodone.All 7 patients reported mild levels(NRS≤2)of cancer pain for 2 days.No serious side effects were reported.The 3-day-type transdermal fentanyl patch conversion by the rapid titration method with short-acting oral oxycodone can be accomplished safely and effectively for patients with moderate cancer pain. SN - 0385-0684 UR - https://www.unboundmedicine.com/medline/citation/22421768/[Three_day_type_transdermal_fentanyl_patch_conversion_by_rapid_titration_method_with_short_acting_oral_oxycodone_for_cancer_pain]_ L2 - http://www.pieronline.jp/openurl?issn=0385-0684&volume=39&issue=3&spage=405 DB - PRIME DP - Unbound Medicine ER -